| Website | valeritas.com/ind... |
| Category | BioTech |
| Phone | 908 927 9920 |
| Employees | |
| Description | Medical device company |
| TOTAL | $150M |
| VENTURE FUNDING TOTAL | $150M |
| Series C, 9/11 MPM Capital Pitango Venture Capital Abingworth Advanced Technology Ventures ONSET Ventures HLM Venture Partners CHL Medical Partners Kaiser Permanente Ventures | $150M |
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas’ medical technologies portfolio is headlined by the h-Patchâ„¢ technology. The first use of the h-Patchâ„¢ technology will be the V-Goâ„¢ disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes. The V-Goâ„¢ is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Goâ„¢ will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes. The h-Patchâ„¢ technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs. V-Goâ„¢ is the brand name for the disposable insulin delivery device which utilizes the h-Patchâ„¢ technology for continuous insulin delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes. The original h-Patch product (BIDS) received 510(k) clearance in 2005 and based on improvements to this technology and its filling device, a new 510(k) for the V-Go and its Filling device was submitted and is currently under review by the FDA.
